Log in

NASDAQ:CHMA - Chiasma Stock Price, Forecast & News

$4.61
+0.04 (+0.88 %)
(As of 02/19/2020 08:07 AM ET)
Today's Range
$4.55
Now: $4.61
$4.68
50-Day Range
$4.55
MA: $4.77
$5.18
52-Week Range
$3.88
Now: $4.61
$9.25
Volume164,251 shs
Average Volume232,338 shs
Market Capitalization$193.71 million
P/E RatioN/A
Dividend YieldN/A
Beta1.16
Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CHMA
CUSIPN/A
Phone617-928-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.40 per share

Profitability

Net Income$-31,260,000.00

Miscellaneous

Employees18
Market Cap$193.71 million
Next Earnings Date3/13/2020 (Estimated)
OptionableNot Optionable

Receive CHMA News and Ratings via Email

Sign-up to receive the latest news and ratings for CHMA and its competitors with MarketBeat's FREE daily newsletter.


Chiasma (NASDAQ:CHMA) Frequently Asked Questions

What is Chiasma's stock symbol?

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

How were Chiasma's earnings last quarter?

Chiasma Inc (NASDAQ:CHMA) posted its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.01. View Chiasma's Earnings History.

When is Chiasma's next earnings date?

Chiasma is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Chiasma.

What price target have analysts set for CHMA?

6 equities research analysts have issued 1 year price objectives for Chiasma's shares. Their forecasts range from $11.00 to $18.00. On average, they expect Chiasma's share price to reach $13.80 in the next twelve months. This suggests a possible upside of 199.3% from the stock's current price. View Analyst Price Targets for Chiasma.

What is the consensus analysts' recommendation for Chiasma?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chiasma.

Has Chiasma been receiving favorable news coverage?

Press coverage about CHMA stock has been trending very negative recently, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Chiasma earned a coverage optimism score of -3.7 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Chiasma.

Are investors shorting Chiasma?

Chiasma saw a decrease in short interest in January. As of January 31st, there was short interest totalling 1,600,000 shares, a decrease of 10.1% from the January 15th total of 1,780,000 shares. Based on an average trading volume of 275,500 shares, the short-interest ratio is presently 5.8 days. Approximately 5.3% of the shares of the stock are short sold. View Chiasma's Current Options Chain.

Who are some of Chiasma's key competitors?

What other stocks do shareholders of Chiasma own?

Who are Chiasma's key executives?

Chiasma's management team includes the folowing people:
  • Mr. Mark J. Fitzpatrick, Pres, CEO, Sec. & Director (Age 56)
  • Mr. Drew Enamait, VP of Fin. & Admin. and Principal Accounting Officer (Age 45)
  • Dr. William H. Ludlam, Sr. VP of Clinical Devel. & Medical Affairs (Age 54)
  • Dr. Gary Patou, Head of Clinical (Age 60)

When did Chiasma IPO?

(CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Who are Chiasma's major shareholders?

Chiasma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (3.57%), Ikarian Capital LLC (2.63%), State Street Corp (1.42%), Renaissance Technologies LLC (1.37%), J. Goldman & Co LP (0.83%) and Bank of New York Mellon Corp (0.25%). Company insiders that own Chiasma stock include Mark J Fitzpatrick, Roni Mamluk, Scott Minick and William Ludlam. View Institutional Ownership Trends for Chiasma.

Which institutional investors are selling Chiasma stock?

CHMA stock was sold by a variety of institutional investors in the last quarter, including J. Goldman & Co LP and Point72 Asset Management L.P.. View Insider Buying and Selling for Chiasma.

Which institutional investors are buying Chiasma stock?

CHMA stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, State Street Corp, California Public Employees Retirement System, Barclays PLC, ProShare Advisors LLC, UBS Group AG, Virtu Financial LLC and Alambic Investment Management L.P.. Company insiders that have bought Chiasma stock in the last two years include Mark J Fitzpatrick, Scott Minick and William Ludlam. View Insider Buying and Selling for Chiasma.

How do I buy shares of Chiasma?

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Chiasma's stock price today?

One share of CHMA stock can currently be purchased for approximately $4.61.

How big of a company is Chiasma?

Chiasma has a market capitalization of $193.71 million. The biotechnology company earns $-31,260,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis. Chiasma employs 18 workers across the globe.View Additional Information About Chiasma.

What is Chiasma's official website?

The official website for Chiasma is http://www.chiasmapharma.com/.

How can I contact Chiasma?

Chiasma's mailing address is 460 Totten Pond Road Suite 530, Waltham MA, 02451. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]


MarketBeat Community Rating for Chiasma (NASDAQ CHMA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  231 (Vote Outperform)
Underperform Votes:  242 (Vote Underperform)
Total Votes:  473
MarketBeat's community ratings are surveys of what our community members think about Chiasma and other stocks. Vote "Outperform" if you believe CHMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel